Published in Heart Disease Weekly, September 4th, 2005
Scientists in France report, "We conducted a multicenter double-blind pharmacokinetic/pharmacodynamic (PK/PD) study of the new oral thromboxane receptor antagonist S18886 in 30 patients with peripheral artery disease who were randomized to receive five different oral dosages of S18886 (1, 2.5, 5, 10 or 30 mg) for 12 weeks (83 days). Our primary objective was to determine the effect of S18886 on platelet aggregation ex vivo."
P. Gaussem and colleagues of INSERM U428 in Paris reported, "Pharmacokinetics of S18886 was linear, with peak plasma levels being reached between 30...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Heart Disease Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.